ArticleOncotarget2018
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.
Niamh McGivern et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this papercites it
ArticleOncotarget2018
Niamh McGivern et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.